• Alcon posted a press release on a non-exclusive collaboration with RxSight to develop adjustable presbyopia-correcting intraocular lenses.
• RxSight to receive USD 60 million upfront; eligible for up to USD 140 million tied to development and regulatory milestones.
• Alcon to lead global commercialization; RxSight to handle development and manufacturing, earning royalties on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alcon AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202607061615BIZWIRE_USPR_____20260702_BW035569) on July 06, 2026, and is solely responsible for the information contained therein.